Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Nanomedicine. 2022 Oct 17;47:102614. doi: 10.1016/j.nano.2022.102614

Figure 4. Immune protection against influenza viruses of homologous, heterologous, and heterosubtypic NA.

Figure 4.

A, B. Bodyweight monitoring and survival rate post homologous NA virus challenge. Challenge dose: A. 5×LD50 rViet (H5N1); B. 5×LD50 Aichi (H3N2). C, D. Bodyweight monitoring and survival rate post heterologous and heterosubtypic NA virus challenge. Challenge dose: C.3×LD50 PR8 (H1N1). D. 3×LD50 Shanghai (H7N9). (*p<0.05, ns, no significance; n=5 for A-B; n=4 for C-D).